PEAK6’s Immunovant IMVT Stock Holding History

PEAK6’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,400	Closed	-$391K	–	2986
2025 Q4	$391K	Hold	15,400	–	–	﹤0.01%	2194
2025 Q3	$248K	Buy	+15,400	New	+$249K	﹤0.01%	2408

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PEAK6's IMVT Position: Q2 2026 in Review

PEAK6 reduced its Immunovant (IMVT) stake by 54% in Q2 2026, selling an estimated $143K and leaving 4,000 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

PEAK6 first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. The position peaked at $216K in Q1 2026. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

PEAK6 held 4,000 shares of Immunovant worth $154K as of Q2 2026.
PEAK6 sold 4,709 Immunovant shares in Q2 2026, an estimated $143K.
Immunovant made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2332 holding.
PEAK6 first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
PEAK6's Immunovant position peaked at $216K in Q1 2026.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.